Drug Trial Radar · NCT04739826
Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
491
Planned (sponsor's estimate)
Start
Sep 25, 2020
Primary completion
Jan 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 5, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ultimate goal of CML treatment is to improve survival, including overall survival (OS), progression-free survival (PFS), event-free survival (EFS), and treatment-free remission (TFR). TFR is a new therapeutic goal for chronic myeloid leukemia in chronic phase (CML-CP). In ENESTnd and DASISION trials, both nilotinib and dasatinib achieved DMR more effectively than imatinib. In the guidelines for diagnosis and treatment of chronic myeloid leukemia in China (2020 edition), flumatinib has been recommended as an appropriate first-line treatment for newly diagnosed chronic phase chronic myeloid leukemia (CML-CP) patients. There is no doubt that the second-generation TKIs show great advantages in deep molecular response, which further increases the possibility of achieving treatment-free remission. However, there is no direct comparative study to determine which TKI is better for de novo CML-CP. Thus, we conducted a multi-center, open-lable and real world study to compare the efficacy and safety between flumatinib and nilotinib.
Conditions
- CML, Chronic Phase; TKI
Interventions
Flumatinib MesylateDrug
Flumatinib mesylate tablets 600mg qd
Nilotinib PillDrug
Nilotinib Capsules 300mg bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major molecular response rate at 12 monthsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Suzhou, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.